The 12 references in paper S. Chikina Yu., С. Чикина Ю. (2016) “Применение комбинации вилантерол / умеклидиния бромид в качестве базисной терапии у пациентов с хронической обструктивной болезнью легких // Vilanterol / umeclidinium bromide combination as a basic therapy for chronic obstructive pulmonary disease” / spz:neicon:pulmonology:y:2016:i:1:p:79-84

1
Cazzola M., Molimard M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm. Pharmacol. Ther. 2010; 23 (4): 257–267.
(check this in PDF content)
2
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Updated 2015. http://www.goldcopd.org/uploads/users/files/ GOLD_Report_2013_Feb20.pdf
(check this in PDF content)
3
Coleman C.I., Limone B., Sobieraj D.M. et al. Dosing frequency and medication adherence in chronic disease. J. Manag. Care Pharm. 2012; 18 (7): 527–539.
(check this in PDF content)
4
Decramer M., Anzueto A., Kerwin E. et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir. Med.2014; 2 (6): 472–486.
(check this in PDF content)
5
Celli B., Crater G., Kilbride S. et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest. 2014; 145 (5): 981–991.
(check this in PDF content)
6
Donohue J.F., Maleki-Yazdi M.R., Kilbride S. et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir. Med.2013; 107 (10): 1538–1546.
(check this in PDF content)
7
Cazzola M., MacNee W., Martinez F.J. et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers.Eur. Respir. J.2008; 31 (2): 416–469.
(check this in PDF content)
8
O'Donnell D.E., Lam M., Webb K.A. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.1998; 158 (5, Pt 1): 1557–1565.
(check this in PDF content)
9
Maltais F., Singh S., Donald A.C. et al. Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials. Ther. Adv. Respir. Dis. 2014; 8 (6): 169–181.
(check this in PDF content)
10
Maleki-Yazdi M.R., Kaelin T., Richard N. et al. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir. Med. 2014; 108 (12): 1752–1760.
(check this in PDF content)
11
Svedsater H., Jacques L., Goldfrad C., Bleecker E.R. Ease of use of the Ellipta dry powder inhaler: data from three randomized controlled trials in patients with asthma. Primary Care Respir. Med. 2014; 24: 14019. doi: 10.1038/npjpcrm. 2014.19
(check this in PDF content)
12
Svedsater H., Dale P., Garrill K. et al. Qualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD.BMC Pulm. Med.2013; 13: 72. doi: 10.1186/1471-2466-13-72.
(check this in PDF content)